Format

Send to

Choose Destination
J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1390-3. doi: 10.1136/jnnp.2011.244574. Epub 2011 Aug 8.

Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.

Author information

1
Department of Neurology, Mitate Hospital, 3237 Yugeta, Tagawa 826-0041, Japan. y-sato@ktarn.or.jp

Abstract

BACKGROUND:

Incidence of a fracture, particularly in the hip joint, is high in Parkinson's disease (PD), owing to the immobilisation-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The authors previously demonstrated the lowered incidence of hip fractures in PD by daily administration of risedronate and vitamin D.

METHODS:

This randomised, double-blind, placebo-controlled study was conducted to determine the efficacy of 17.5 mg once-weekly risedronate in the prevention of hip fracture in women with PD. Patients were randomly assigned to 17.5 mg risedronate once a week (n=136) or a placebo (n=136) combined with daily 1000 IU of ergocalciferol. Incidence of hip fractures was compared between the two groups during the 2-year follow-up.

RESULTS:

Hip fractures occurred in 15 patients in the placebo group and 3 patients in the risedronate group. The RR for hip fractures in the risedronate group as compared with the placebo group was 0.20 (95% CI 0.06 to 0.66). In the risedronate group, serum calcium levels decreased during the follow-up, while the levels in the placebo group increased. BMD increased by 3.4% in the risedronate group and decreased by 3.2% in the placebo group (p<0.01).

CONCLUSIONS:

Treatment with once-weekly risedronate and ergocalciferol prevents hip fractures in older women with PD.

PMID:
21825080
DOI:
10.1136/jnnp.2011.244574
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center